This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Avenue Therapeutics, Inc. (ATXI) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.40, moving -1.61% from the previous trading session.
Avenue Therapeutics, Inc. (ATXI) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $9.83, moving -0.91% from the previous trading session.
Revolution Medicines (RVMD) Catches Eye: Stock Jumps 10.2%
by Zacks Equity Research
Revolution Medicines (RVMD) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Avenue Therapeutics, Inc. (ATXI) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $9.75, moving -1.52% from the previous trading session.
Is Avenue Therapeutics (ATXI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ATXI) Outperforming Other Medical Stocks This Year?
Pacira (PCRX) Provides Preliminary Results for Second Quarter
by Zacks Equity Research
Pacira (PCRX) reports preliminary results for the second quarter of 2020. The company's product sales are hurt by the COVID-19 pandemic. The stock fell in pre-market trading.
Zynerba's Zygel Fails in Phase III Fragile X Syndrome Study
by Zacks Equity Research
Zynerba's (ZYNE) shares plunge 48.5% following the study data readout, which demonstrated failure to achieve statistical significance in primary endpoint.
Alpine Begins Dosing in Phase I Study for Advanced Malignancies
by Zacks Equity Research
Alpine (ALPN) doses the first patient in the phase I NEON-1 study evaluating its pipeline candidate ALPN-202 for treating patients with advanced malignancies.
Veru (VERU) Soars: Stock Adds 6.9% in Session
by Zacks Equity Research
Veru (VERU) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Avenue Therapeutics, Inc. (ATXI) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Applied Genetic (AGTC) Soars: Stock Adds 6.1% in Session
by Zacks Equity Research
Applied Genetic (AGTC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
New Strong Buy Stocks for June 24th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Avenue Therapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Avenue Therapeutics
Aclaris Gets FDA Nod to Start Investigator-led Coronavirus Study
by Zacks Equity Research
Aclaris (ACRS) announces that it supports an IND application to evaluate its oral investigational MK2 inhibitor compound, ATI-450, in hospitalized patients with COVID-19.
NGM Biopharmaceuticals (NGM) Soars: Stock Adds 7.8% in Session
by Zacks Equity Research
NGM Biopharmaceuticals (NGM) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Is Avenue Therapeutics (ATXI) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ATXI) Outperforming Other Medical Stocks This Year?
Provention Bio (PRVB) Looks Good: Stock Adds 8.6% in Session
by Zacks Equity Research
Provention Bio (PRVB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Zacks.com featured highlights include: Frontline, iClick Interactive Asia, Avenue Therapeutics, ProQR Therapeutics and BJ???s Wholesale Club
by Zacks Equity Research
Zacks.com featured highlights include: Frontline, iClick Interactive Asia, Avenue Therapeutics, ProQR Therapeutics and BJ???s Wholesale Club
Soleno (SLNO) Looks Good: Stock Adds 6.8% in Session
by Zacks Equity Research
Soleno (SLNO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
5 Low-Beta Stocks to Beat Renewed Coronavirus Concerns
by Nilanjan Banerjee
To combat market volatility, it is of utmost importance to create a portfolio of low-beta stocks.
NantHealth (NH) Looks Good: Stock Adds 9.1% in Session
by Zacks Equity Research
NantHealth (NH) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Otonomy (OTIC) in Focus: Stock Moves 6.1% Higher
by Zacks Equity Research
Otonomy (OTIC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Infinity (INFI) Looks Good: Stock Adds 5.3% in Session
by Zacks Equity Research
Infinity (INFI) saw a big move last session, as its shares jumped nearly 5% on the day, amid huge volumes.
Recro Pharma (REPH) in Focus: Stock Moves 7.6% Higher
by Zacks Equity Research
Recro Pharma (REPH) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Zacks.com featured highlights include: Avenue Therapeutics, Calix, ChannelAdvisor and Magic Software Enterprises
by Zacks Equity Research
Zacks.com featured highlights include: Avenue Therapeutics, Calix, ChannelAdvisor and Magic Software Enterprises